# Anthony L Traboulsee

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2563107/anthony-l-traboulsee-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190	11,241	37	104
papers	citations	h-index	g-index
205	14,847 ext. citations	6.4	5.92
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
190	Cervical Spinal Cord Atrophy can be Accurately Quantified Using Head Images <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2022</b> , 8, 20552173211070760	2	O
189	Cortical morphology predicts placebo response in multiple sclerosis Scientific Reports, <b>2022</b> , 12, 732	4.9	
188	Productivity loss among people with early multiple sclerosis: A Canadian study <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585211069070	5	1
187	Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103366	4	0
186	The reality of multiple sclerosis assessment in middle-income countries - AuthorsQeply <i>Lancet Neurology, The</i> , <b>2022</b> , 21, 215-216	24.1	
185	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. <i>BMC Neurology</i> , <b>2021</b> , 21, 418	3.1	1
184	Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 2191-2198	5	1
183	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. <i>JAMA Neurology</i> , <b>2021</b> , 78, 351-364	17.2	11
182	Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 50, 102809	4	O
181	Corpus callosum lesions are not inextricably linked to CNS symptoms in reported cases of susac syndrome. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 51, 102883	4	1
180	Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211023345	5	1
179	Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2021</b> , 7, 20552173211029966	2	
178	Comparison of multi echo T relaxation and steady state approaches for myelin imaging in the central nervous system. <i>Scientific Reports</i> , <b>2021</b> , 11, 1369	4.9	2
177	Water content changes in new multiple sclerosis lesions have a minimal effect on the determination of myelin water fraction values. <i>Journal of Neuroimaging</i> , <b>2021</b> , 31, 1119-1125	2.8	1
176	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 653-670	24.1	44
175	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 762	2-372	37
174	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 729-738	24.1	19

173	Elevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 56, 103269	4	О
172	An atlas for human brain myelin content throughout the adult life span. Scientific Reports, <b>2021</b> , 11, 269	4.9	11
171	Associations Between Findings From Myelin Water Imaging and Cognitive Performance Among Individuals With Multiple Sclerosis. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2014220	10.4	5
170	Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 189	10.1	17
169	Genetic analysis of nucleotide-binding leucine-rich repeat (NLR) receptors in multiple sclerosis. <i>Immunogenetics</i> , <b>2020</b> , 72, 381-385	3.2	O
168	Both Stationary and Dynamic Functional Interhemispheric Connectivity Are Strongly Associated With Performance on Cognitive Tests in Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 407	4.1	2
167	Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. <i>Journal of Neurology</i> , <b>2020</b> , 267, 3343-3353	5.5	13
166	Myelin water imaging data analysis in less than one minute. <i>NeuroImage</i> , <b>2020</b> , 210, 116551	7.9	14
165	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 402-412	24.1	137
164	Myelin Damage in Normal Appearing White Matter Contributes to Impaired Cognitive Processing Speed in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , <b>2020</b> , 30, 205-211	2.8	9
163	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1866-1876	5	12
162	Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients. <i>Journal of Neuro-Ophthalmology</i> , <b>2020</b> , 40, 37-43	2.6	3
161	Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. <i>Neurology</i> , <b>2020</b> , 95, e1854-e1867	6.5	34
160	Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320926613	2	2
159	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. <i>CNS Drugs</i> , <b>2020</b> , 34, 973-988	6.7	19
158	Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. <i>Neurology</i> , <b>2020</b> , 95, e1999-e2008	6.5	172
157	Myelin Water Fraction and Intra/Extracellular Water Geometric Mean T Normative Atlases for the Cervical Spinal Cord from 3T MRI. <i>Journal of Neuroimaging</i> , <b>2020</b> , 30, 50-57	2.8	8
156	Myelin Water Imaging and Transcranial Magnetic Stimulation Suggest Structure-Function Relationships in Multiple Sclerosis. <i>Frontiers in Physics</i> , <b>2019</b> , 7,	3.9	2

155	Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 30, 236-243	4	42
154	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 185-197	24.1	74
153	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , <b>2019</b> , 142, 1858-1875	11.2	150
152	Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. <i>PLoS Genetics</i> , <b>2019</b> , 15, e1008180	6	26
151	Laboratory Monitoring Practices Among Canadian Multiple Sclerosis Clinicians. <i>Canadian Journal of Neurological Sciences</i> , <b>2019</b> , 46, 389-393	1	
150	Three-dimensional MRI sequences in MS diagnosis and research. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 17	70 <del>9</del> -170	)93
149	Intra- and inter-site reproducibility of human brain single-voxel proton MRS at 3 T. <i>NMR in Biomedicine</i> , <b>2019</b> , 32, e4083	4.4	1
148	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 253	4.1	12
147	Longitudinal advanced MRI case report of white matter radiation necrosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 379-385	5.3	6
146	Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217318824612	2	
145	Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 837-847	5	16
144	Data fusion detects consistent relations between non-lesional white matter myelin, executive function, and clinical characteristics in multiple sclerosis. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 101926	5.3	4
143	Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. <i>BMC Neurology</i> , <b>2019</b> , 19, 173	3.1	8
142	Myelin Water Atlas: A Template for Myelin Distribution in the Brain. <i>Journal of Neuroimaging</i> , <b>2019</b> , 29, 699-706	2.8	16
141	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e583	9.1	23
140	Rapid myelin water imaging for the assessment of cervical spinal cord myelin damage. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101896	5.3	14
139	Association of Unemployment and Informal Care with Stigma in Multiple Sclerosis: Evidence from the Survey on Living with Neurological Conditions in Canada. <i>International Journal of MS Care</i> , <b>2019</b> , 21, 214-225	2.3	4
138	Perspectives About Time Frames in Stem Cell Research for Multiple Sclerosis: "Time Is Brain". <i>International Journal of MS Care</i> , <b>2019</b> , 21, 185-193	2.3	1

137	Effect of different doses of gadolinium contrast agent on clinical outcomes in MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217318823796	2	6
136	Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS. <i>Neurology</i> , <b>2019</b> , 92, 519-533	6.5	25
135	Author response: Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial. <i>Neurology</i> , <b>2019</b> , 93, 320	6.5	
134	Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217319885983	2	12
133	Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217319879952	2	4
132	Multicenter Measurements of T Relaxation and Diffusion Tensor Imaging: Intra and Intersite Reproducibility. <i>Journal of Neuroimaging</i> , <b>2019</b> , 29, 42-51	2.8	11
131	Case of alemtuzumab-related alopecia areata management in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e516	9.1	7
130	Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis. <i>Human Brain Mapping</i> , <b>2019</b> , 40, 2104-2116	5.9	33
129	Diffusely Abnormal White Matter, T Burden of Disease, and Brain Volume in Relapsing-Remitting Multiple Sclerosis. <i>Journal of Neuroimaging</i> , <b>2019</b> , 29, 151-159	2.8	8
128	Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy?. <i>Journal of Magnetic Resonance Imaging</i> , <b>2019</b> , 50, 201-208	5.6	16
127	Deep learning of brain lesion patterns and user-defined clinical and MRI features for predicting conversion to multiple sclerosis from clinically isolated syndrome. <i>Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization</i> , <b>2019</b> , 7, 250-259	0.9	9
126	A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 811-818	5	15
125	Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 20, 37-42	4	18
124	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 162-173	24.1	2419
123	What Have We Learned from Perfusion MRI in Multiple Sclerosis?. <i>American Journal of Neuroradiology</i> , <b>2018</b> , 39, 994-1000	4.4	29
122	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318760642	2	19
121	Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiplesclerosis patients and healthy controls. <i>NeuroImage: Clinical</i> , <b>2018</b> , 17, 169-178	5.3	46
120	Analysis of NOD-like receptor NLRP1 in multiple sclerosis families. <i>Immunogenetics</i> , <b>2018</b> , 70, 205-207	3.2	10

119	Resilience, trust, and civic engagement in the post-CCSVI era. <i>BMC Health Services Research</i> , <b>2018</b> , 18, 366	2.9	2
118	Common variation near IRF6 is associated with IFN-EInduced liver injury in multiple sclerosis. <i>Nature Genetics</i> , <b>2018</b> , 50, 1081-1085	36.3	28
117	Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents. <i>American Journal of Neuroradiology</i> , <b>2018</b> , 39, 1597-1603	4.4	15
116	Perspectives of Patients with Multiple Sclerosis on Drug Treatment: A Qualitative Study. <i>International Journal of MS Care</i> , <b>2018</b> , 20, 269-277	2.3	10
115	Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1557-1568	5	24
114	060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A25.1-A25	5.5	
113	Inter-Vendor Reproducibility of Myelin Water Imaging Using a 3D Gradient and Spin Echo Sequence. <i>Frontiers in Neuroscience</i> , <b>2018</b> , 12, 854	5.1	16
112	Goodpasture@Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis. <i>Canadian Journal of Neurological Sciences</i> , <b>2018</b> , 45, 712-714	1	3
111	Education, and the balance between dynamic and stationary functional connectivity jointly support executive functions in relapsing-remitting multiple sclerosis. <i>Human Brain Mapping</i> , <b>2018</b> , 39, 5039-5049	95.9	21
110	Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial. <i>Neurology</i> , <b>2018</b> , 91, e1660-e1668	6.5	15
109	Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. <i>BMC Neurology</i> , <b>2018</b> , 18, 143	3.1	8
108	Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study. <i>BMC Neurology</i> , <b>2018</b> , 18, 68	3.1	O
107	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 24, 11-19	4	12
106	Reflections on translation: Views of participants in a multisite Canadian CCSVI clinical trial. Neurology: Clinical Practice, <b>2018</b> , 8, 232-239	1.7	
105	Anisotropic cerebral vascular architecture causes orientation dependency in cerebral blood flow and volume measured with dynamic susceptibility contrast magnetic resonance imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2017</b> , 37, 1108-1119	7.3	22
104	Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry. <i>Canadian Journal of Neurological Sciences</i> , <b>2017</b> , 44, 246-254	1	4
103	Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis. <i>Human Mutation</i> , <b>2017</b> , 38, 736-744	<b>1</b> 4.7	29
102	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 658-665	13.6	76

## (2017-2017)

1	101	Genetic modifiers of multiple sclerosis progression, severity and onset. <i>Clinical Immunology</i> , <b>2017</b> , 180, 100-105	9	14
1	100	Evaluating the safety of Enterferons in MS: A series of nested case-control studies. <i>Neurology</i> , <b>2017</b> , 88, 2310-2320	6.5	29
Ş	99	Susceptibility-sensitive MRI of multiple sclerosis lesions and the impact of normal-appearing white matter changes. <i>NMR in Biomedicine</i> , <b>2017</b> , 30, e3727	4.4	25
Ş	98	Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017. <i>Multiple Sclerosis and Related Disorders</i> ,	4	4
9	97	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , <b>2017</b> , 7, e016276	3	2
Ş	96	Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2122-2133	59.2	111
9	95	Common genetic etiology between "multiple sclerosis-like" single-gene disorders and familial multiple sclerosis. <i>Human Genetics</i> , <b>2017</b> , 136, 705-714	6.3	9
ç	94	Cognitive Performance in Subjects With Multiple Sclerosis Is Robustly Influenced by Gender in Canonical-Correlation Analysis. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2017</b> , 29, 119-127	2.7	8
Ş	93	Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study. <i>Canadian Association of Radiologists Journal</i> , <b>2017</b> , 68, 202-209	3.9	4
ç	92	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 221-234	59.2	858
9	91	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 209-220	59.2	88o
Ş	90	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , <b>2017</b> , 89, 1107-1116	6.5	139
8	39	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , <b>2017</b> , 89, 1117-1126	i 6.5	175
8	38	Characterization of brain tumours with spin-spin relaxation: pilot case study reveals unique T distribution profiles of glioblastoma, oligodendroglioma and meningioma. <i>Journal of Neurology</i> , <b>2017</b> , 264, 2205-2214	5.5	4
8	<sup>3</sup> 7	Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. <i>NeuroImage: Clinical</i> , <b>2017</b> , 16, 17-22	5.3	17
8	36	Rapid myelin water imaging in human cervical spinal cord. <i>Magnetic Resonance in Medicine</i> , <b>2017</b> , 78, 1482-1487	4.4	18
8	35	PO129 Neda analysis by epoch in the opera studies of ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A46.2-A46	5.5	1
8	<sup>3</sup> 4	Hierarchical Multimodal Fusion of Deep-Learned Lesion and Tissue Integrity Features in Brain MRIs for Distinguishing Neuromyelitis Optica from Multiple Sclerosis. <i>Lecture Notes in Computer Science</i> , <b>2017</b> , 480-488	0.9	3

83	Corticospinal tract integrity measured using transcranial magnetic stimulation and magnetic resonance imaging in neuromyelitis optica and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 43-50	5	14
82	Addressing Concerns Regarding the Use of Gadolinium in a Standardized MRI Protocol for the Diagnosis and Follow-Up of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , <b>2016</b> , 37, E82-E83	4.4	9
81	Deep Learning of Brain Lesion Patterns for Predicting Future Disease Activity in Patients with Early Symptoms of Multiple Sclerosis. <i>Lecture Notes in Computer Science</i> , <b>2016</b> , 86-94	0.9	15
80	Case-Control Studies Are Not Familial Studies. <i>Neuron</i> , <b>2016</b> , 92, 339-341	13.9	9
79	Longitudinal Study of Retinal Nerve Fiber Layer Thickness and Macular Volume in Patients With Neuromyelitis Optica Spectrum Disorder. <i>Journal of Neuro-Ophthalmology</i> , <b>2016</b> , 36, 363-368	2.6	20
78	Does hydration status affect MRI measures of brain volume or water content?. <i>Journal of Magnetic Resonance Imaging</i> , <b>2016</b> , 44, 296-304	5.6	25
77	Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. <i>Neuron</i> , <b>2016</b> , 90, 948-54	13.9	59
76	Quantitative analysis of multiple sclerosis patients@references for drug treatment: a best-worst scaling study. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2016</b> , 9, 287-96	6.6	25
75	FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection. <i>American Journal of Neuroradiology</i> , <b>2016</b> , 37, 259-65	4.4	27
74	Analysis of CH25H in multiple sclerosis and neuromyelitis optica. <i>Journal of Neuroimmunology</i> , <b>2016</b> , 291, 70-2	3.5	9
73	Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , <b>2016</b> , 37, 394-401	4.4	209
72	Brain health: time matters in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 9 Suppl 1, S5-S48	4	189
71	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , <b>2016</b> , 6, 2073-9	3.2	8
70	Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2016</b> , 2, 2055217316666406	2	5
69	Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica. <i>NeuroImage: Clinical</i> , <b>2016</b> , 11, 743-750	5.3	31
68	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , <b>2015</b> , 85, 177-89	6.5	2255
67	An assessment of genetic counseling services for individuals with multiple sclerosis. <i>Journal of Genetic Counseling</i> , <b>2015</b> , 24, 46-57	2.5	2
66	Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. <i>Canadian Journal of Neurological Sciences</i> , <b>2015</b> , 42, 159-67	1	14

### (2013-2015)

65	Health-related quality of life in patients with longstanding <b>Q</b> enign multiple sclerosis <i>QMultiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 31-8	4	8
64	Incidence of Multiple Sclerosis and Related Disorders in Asian Populations of British Columbia. <i>Canadian Journal of Neurological Sciences</i> , <b>2015</b> , 42, 235-41	1	7
63	Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker. <i>NeuroImage: Clinical</i> , <b>2015</b> , 9, 574-80	5.3	36
62	Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2015</b> , 1, 2055217315577829	2	
61	Fast computation of myelin maps from MRI Tirelaxation data using multicore CPU and graphics card parallelization. <i>Journal of Magnetic Resonance Imaging</i> , <b>2015</b> , 41, 700-7	5.6	11
60	Orientation Dependent MR Signal Decay Differentiates between People with MS, Their Asymptomatic Siblings and Unrelated Healthy Controls. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140956	3.7	22
59	Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 101-4	5	1
58	Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137715	3.7	31
57	Brain health: time matters in multiple sclerosis 2015,		5
56	Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. <i>Lancet, The</i> , <b>2014</b> , 383, 138-45	40	70
55	Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression. <i>Neurogenetics</i> , <b>2014</b> , 15, 165-9	3	25
54	Detection of Unusual Increases in MRI Lesion Counts in Individual Multiple Sclerosis Patients. Journal of the American Statistical Association, <b>2014</b> , 109, 119-132	2.8	3
53	Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. <i>CNS Drugs</i> , <b>2014</b> , 28, 475-82	6.7	7
52	Progressive multiple sclerosis does not associate with rs996343 and rs2046748. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 766-7	5	1
51	Analysis of CYP27B1 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 266, 64-6	3.5	16
50	Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning. <i>Lecture Notes in Computer Science</i> , <b>2014</b> , 17, 462-9	0.9	24
49	Obstetrical epidural and spinal anesthesia in multiple sclerosis. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2620-8	5.5	24
48	Association of smoking with risk of multiple sclerosis: a population-based study. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1778-81	5.5	32

47	Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. <i>Neuroscience Bulletin</i> , <b>2013</b> , 29, 525-30	4.3	13
46	Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. <i>Expert Review of Neurotherapeutics</i> , <b>2013</b> , 13, 251-60; quiz 261	4.3	26
45	Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. <i>Multiple Sclerosis and Related Disorders</i> , <b>2013</b> , 2, 57-9	4	8
44	Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. <i>Journal of Neuro-Ophthalmology</i> , <b>2013</b> , 33, 213-9	2.6	38
43	Characterising aggressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1192-8	5.5	51
42	Magnetic resonance frequency shifts during acute MS lesion formation. <i>Neurology</i> , <b>2013</b> , 81, 211-8	6.5	50
41	Retinal nerve fiber layer thickness in benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1275	i- <b>§</b> 1	22
40	Pathological correlates of magnetic resonance imaging texture heterogeneity in multiple sclerosis. <i>Annals of Neurology</i> , <b>2013</b> , 74, 91-9	9.4	39
39	Multicenter measurements of myelin water fraction and geometric mean T2: intra- and intersite reproducibility. <i>Journal of Magnetic Resonance Imaging</i> , <b>2013</b> , 38, 1445-53	5.6	50
38	Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2013</b> , 72, 42-52	3.1	41
37	Treatment of Neuromyelitis Optica: Review and Recommendations. <i>Multiple Sclerosis and Related Disorders</i> , <b>2012</b> , 1, 180-187	4	176
36	Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis. <i>NeuroImage: Clinical</i> , <b>2012</b> , 1, 29-36	5.3	7
35	Comparison of MERGE and axial T2-weighted fast spin-echo sequences for detection of multiple sclerosis lesions in the cervical spinal cord. <i>American Journal of Roentgenology</i> , <b>2012</b> , 199, 157-62	5.4	35
34	Time-Domain and Spectral-Domain Optical Coherence Tomography of Retinal Nerve Fiber Layer in MS Patients and Healthy Controls. <i>Journal of Ophthalmology</i> , <b>2012</b> , 2012, 564627	2	18
33	Short-term stability of T1 and T2 relaxation measures in multiple sclerosis normal appearing white matter. <i>Journal of Neurology</i> , <b>2012</b> , 259, 1151-8	5.5	14
32	Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1278-89	5	112
31	Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon [1] b trial in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 282-7	5.5	76
<b>3</b> 0	Reproducibility of retinal nerve fiber layer measurements with manual and automated centration in healthy subjects using spectralis spectral-domain optical coherence tomography. <i>ISRN Ophthalmology</i> , <b>2012</b> , 2012, 860819		3

#### (2007-2011)

29	Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. <i>PLoS ONE</i> , <b>2011</b> , 6, e22444	3.7	27
28	Is the magnetization transfer ratio a marker for myelin in multiple sclerosis?. <i>Journal of Magnetic Resonance Imaging</i> , <b>2011</b> , 33, 713-8	5.6	133
27	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , <b>2011</b> , 70, 897-912	9.4	263
26	Targeting progressive neuroaxonal injury: lessons from multiple sclerosis. <i>CNS Drugs</i> , <b>2011</b> , 25, 783-99	6.7	21
25	Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2011</b> , 4, 3-14	6.6	38
24	Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 144-50	5	51
23	Postvaccination Miller Fisher syndrome. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1327-9		15
22	Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 532-40	5	16
21	Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. <i>Clinical Therapeutics</i> , <b>2009</b> , 31, 1724-36	3.5	29
20	Reproducibility of myelin water fraction analysis: a comparison of region of interest and voxel-based analysis methods. <i>Magnetic Resonance Imaging</i> , <b>2009</b> , 27, 1096-103	3.3	52
19	. IEEE Journal on Selected Topics in Signal Processing, <b>2008</b> , 2, 907-918	7·5	3
18	Conventional MR imaging. <i>Neuroimaging Clinics of North America</i> , <b>2008</b> , 18, 651-73, x	3	19
17	Complementary information from multi-exponential T2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions. <i>NeuroImage</i> , <b>2008</b> , 40, 77-85	7.9	40
16	Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. <i>Neurology</i> , <b>2008</b> , 70, 1092-7	6.5	25
15	MRI relapses have significant pathologic and clinical implications in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 256 Suppl 1, S19-22	3.2	14
14	MR evidence of long T2 water in pathological white matter. <i>Journal of Magnetic Resonance Imaging</i> , <b>2007</b> , 26, 1117-21	5.6	52
13	Long T2 water in multiple sclerosis: what else can we learn from multi-echo T2 relaxation?. <i>Journal of Neurology</i> , <b>2007</b> , 254, 1579-87	5.5	51
12	Longitudinal, regional and deformation-specific corpus callosum shape analysis for multiple sclerosis. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , <b>2007</b> , 2007, 2110-3		4

11	Invariant SPHARM shape descriptors for complex geometry in MR region of interest analysis.  Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 132	22-5	7	
10	Brain extraction using geodesic active contours 2006,		2	
9	Optimal Filter Design for Multiple Sclerosis Lesions Segmentation from Regions of Interest in Brain MRI <b>2006</b> ,		3	
8	MRI Brain Extraction with Combined Expectation Maximization and Geodesic Active Contours 2006,		15	
7	Effects of Mid-Sagittal Plane Perturbation and Image Interpolation on Corpus Callosum Area Calculation <b>2006</b> ,		1	
6	Semi-Automated Segmentation of Multiple Sclerosis Lesions in Brain MRI using Texture Analysis <b>2006</b> ,		3	
5	The role of MRI in the diagnosis of multiple sclerosis. Advances in Neurology, 2006, 98, 125-46		44	
4	The use of MRI as an outcome measure in clinical trials. <i>Advances in Neurology</i> , <b>2006</b> , 98, 203-26		14	
3	Neuroimaging in multiple sclerosis. <i>Neurologic Clinics</i> , <b>2005</b> , 23, 131-48, vii	4.5	13	
2	MRI: role in optimising treatment. <i>Journal of Neurology</i> , <b>2004</b> , 251 Suppl 5, v36-v41	5.5	1	
1	The role of diffusion and perivascular spaces in dynamic susceptibility contrast MRI		7	